Articles
| Open Access |
DOI: DESIGN AND OPTIMIZATION OF EVEROLIMUS-LOADED PROTEIN NANOPARTICLES FOR TARGETED THERAPY OF GLIOBLASTOMAS
Deepa Pathak , Parul Institute of Pharmacy and Research, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, IndiaAbstract
Glioblastoma is a highly aggressive and difficult-to-treat brain cancer with limited therapeutic options. This study aims to design and optimize protein nanoparticles loaded with Everolimus, a potent anticancer drug, for targeted therapy of glioblastomas. The protein nanoparticles were formulated using a biodegradable protein matrix and characterized for physicochemical properties, drug encapsulation efficiency, and drug release kinetics. Cellular uptake studies were conducted to assess the internalization of nanoparticles by glioblastoma cells. The results demonstrate uniform size distribution, stable surface charge, high drug loading efficiency, sustained drug release, and efficient cellular uptake of Everolimus-loaded protein nanoparticles. This research highlights the potential of protein nanoparticles as a promising strategy for improving the treatment outcomes of glioblastomas.
Keywords
Glioblastoma, protein nanoparticles, targeted therapy
References
Gao M, Mei D, Huo Y, Mao S. Effect of polysorbate 80 on the intranasal absorption and brain distribution of tetramethylpyrazine phosphate in rats. Drug delivery and translational research. 2019 Feb 15;9(1):311-8.
Muankaew C, Loftsson T. Cyclodextrin‐based formulations: a non‐invasive platform for targeted drug delivery. Basic & clinical pharmacology & toxicology. 2018 Jan;122(1):46-55.
21) Shah B, Khunt D, Misra M, Padh H. Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharmaceutical research. 2018 Jan;35(1):1-0.
Dayal P, Shaik MS, Singh M. Evaluation of different parameters that affect droplet‐size distribution from nasal sprays using the Malvern Spraytec®. Journal of pharmaceutical sciences. 2004 Jul 1;93(7):1725-42.
Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. European Neuropsychopharmacology. 2013 Oct 1;23(10):1190-8.
Ferreira, S. L. C. et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal. Chim. Acta 597, 179–186 (2007).
Box, G. E. P. & Behnken, D. Some New Three Level Designs for the Study of Quantitative Variables. Technometrics 2, 455–475 (1960).
Article Statistics
Copyright License
Copyright (c) 2023 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.